T
here has been a re-emergence of tuberculosis as a global health problem over the past two decades 1 2 accompanied by an increase in drug resistant tuberculosis strains. 3 In response to this problem and to help to inform public health policy, a system to monitor trends in drug resistant tuberculosis was developed in 1993 in the UK.
The UK Mycobacterial Resistance Network (Mycobnet) collects information on all bacteriologically confirmed cases of tuberculosis where a culture has been submitted to one of the mycobacterial reference and regional centres nationwide. 4 In this paper the nature and magnitude of drug resistance in newly diagnosed cases of tuberculosis in the UK between 1993 and 1999 using data collated by Mycobnet is presented.
METHODS
UK reference and regional laboratories collect a minimum dataset on individuals from whom an initial isolate of Mycobacterium tuberculosis complex (M tuberculosis, M bovis, or M africanum) has been isolated and submitted by source hospital laboratories. Data sought include susceptibility to first line antibiotics, demographic, geographical, and other risk factor information. An initial isolate is defined as the first positive culture from a person from whom no positive culture had been recorded during the past 12 months. First line antibiotics are isoniazid, rifampicin, ethambutol, and pyrazinamide. Monoresistance was defined as resistance to only one of the first line antibiotics or to streptomycin alone. Multidrug resistance (MDR) was defined as resistance to at least isoniazid and rifampicin. UK reference laboratories employ the resistance ratio method using solid media as well as the proportional radiometric method using the Bactec system to test for drug susceptibility. 5 Since M bovis isolates are intrinsically resistant to pyrazinamide, 6 7 these were excluded from estimates of pyrazinamide resistance.
The Mycobnet dataset was matched by SOUNDEX code 8 and date of birth to the national AIDS/HIV databases at CDSC to make an estimate of the association of antibiotic resistance with HIV status. Data from 1998 and 1999 only were used for analysis of drug resistance by ethnic group and previous history of tuberculosis as ethnic grouping data are very limited in the Mycobnet dataset before 1998. The term "Oriental ethnic origin" was used to represent those ethnic groups indigenous to China and the south-east Asian area.
Analysis was performed using Epi-Info version 6.04c 9 including data from 1993 to 1999 received by November 2000. Trend analyses excluded 1993 data as it was collected retrospectively and is not strictly comparable with data for subsequent years. 4 The proportion of isolates resistant to the first line antituberculosis drugs (either monoresistant or in combination with resistance to other first line drugs) was calculated with 95% confidence intervals. A χ 2 test was used to test the difference in proportions and χ 2 for trend was used to assess any changes in drug resistance over time. 
RESULTS

All isolates
Sex and age
Information on patient's age was available for 24 288 isolates (96.3%). Of these, 12 268 (50.5%) were from patients aged 15-44 years. A slightly higher proportion of isoniazid (significantly higher than in those aged >44 years) and multidrug resistance (significantly higher than in those aged >65 years) was observed in those aged 15-44 years than in other age groups.
Information on sex was available in 96% (24 263) of all isolates (table 2) . Of these, 14 214 (59%) were men. The proportion of isoniazid resistant tuberculosis was higher in men than in women, although the difference was not significant. However, men were significantly more likely to have MDR tuberculosis (1.4% v 0.9%; χ 2 12.38, OR 1.57, p<0.001).
Ethnicity and place of birth Ethnicity was reported in 13 867 (55%) of patients with initial isolates ( 
Secular trends
The total number of initial isolates increased gradually from 3253 in 1994 to 4260 in 1999. The proportion of isolates resistant to isoniazid increased from 5.6% in 1994 to 5.9% in 1999, but this difference was not significant (table 3) . The proportion of MDR isolates decreased significantly from 1.3% in 1994 to 0.8% in 1999 (trend analysis: χ 2 6.7, p=0.009).
Geographical distribution
The proportion of isoniazid resistance was higher in residents of England than in the other areas of the UK (χ 2 587, 3 df, p<0.001) as was the proportion with MDR tuberculosis (χ 2 10.04, 3 df, p=0.01, 
Site of disease
Between 1993 and 1999, 14 689 isolates (58%) were from cases who had pulmonary disease with or without nonpulmonary disease. Of these, 10 904 (74%) had an initial positive culture from a sputum specimen, of which 6031 (56%) were smear positive. Pulmonary disease was found in 62.3% of men and 54.1% of women (χ 2 162.26, p<0.001, odds ratio 1.4). Among isolates from people with pulmonary disease, 5.8% were resistant to isoniazid, similar to the 5.4% of isolates from other cases. The proportion of MDR isolates was higher in pulmonary than in non-pulmonary cases (1.5% v 0.8%, χ 2 23.77, p=0.000001, odds ratio 1.9).
Overall, 42% of MDR isolates and 30% of isoniazid resistant isolates were from patients with sputum smear positive Isoniazid resistance, previous tuberculosis, and ethnic group Both monoresistance to isoniazid and any resistance to isoniazid were lower in those with no previous history of tuberculosis and of white ethnic origin and highest in those of black African and Oriental ethnic origin (based on data from 1998 and 1999). Comparisons of levels of isoniazid resistance between ethnic groups in those with a previous history of tuberculosis or an unknown previous history of tuberculosis are difficult to make because of the low numbers of cases (table 4) .
Monoresistance and resistance to more than one first line drug A total of 12 692 isolates were tested for sensitivity to isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin. Isolates not tested against all five drugs and M bovis isolates were excluded from this analysis.
The highest level of resistance was to isoniazid and, among resistant isolates, resistance to isoniazid was most likely to be monoresistance (χ 2 260.24, df 4, p<0.001; table 5). Monoresistance to streptomycin was also relatively common. Of these 12 692 isolates, 264 (2.1%) were MDR, of which 88 (33.3%) showed no resistance to ethambutol, pyrazinamide, or streptomycin. While 22.1% of all isoniazid resistant isolates were also rifampicin resistant, 88.3% of rifampicin resistant isolates were also resistant to isoniazid. Combined resistance to isoniazid and streptomycin was found in 396 (3.1%) of the 12 692 isolates, of which 257 (64.9%) showed no resistance to ethambutol, rifampicin, or pyrazinamide.
DISCUSSION
Drug resistant tuberculosis in countries with good national control programmes such as the UK and others in Western Europe 10 11 is not commonly a major public health problem although, with increasing migration, there is a need to remain vigilant.
The overall level of drug resistance in the UK remained stable and low during the mid to late 1990s. A small but significant decrease in the proportion of MDR tuberculosis was observed, but this finding may be partly due to an increase in the number of MDR cases in 1995 and 1996 resulting from two major outbreaks of hospital acquired MDR tuberculosis in HIV *Any: resistance to specified drug, with or without resistance to other drugs. †Mono: resistance to specified drug alone.
positive patients. 12 13 The small increase in the proportion of isoniazid resistant isolates between 1994 and 1999 was not statistically significant.
Certain groups of people appear to be at a higher risk of acquiring drug resistant tuberculosis. Men have higher levels of drug resistance generally, and a significantly higher proportion of multidrug resistance. These findings could either be due to the fact that men are less compliant with drug treatment or because of other risk factors associated with the male sex (homelessness, alcohol misuse, and HIV infection).
Resistance was higher among patients resident in London than in the rest of the UK, as reported previously. 4 Factors that may contribute to this problem in the capital are an increase in tuberculosis case numbers, immigration from countries with a high incidence of resistant tuberculosis, co-infection with HIV, and social problems such as overcrowding and poverty.
14 The NHS Executive report on tuberculosis control in London suggests that the high demand on health services may not be met adequately in the city. 15 A universal approach to supervised drug taking in the initial treatment stage for sputum smear positive cases in areas with a high prevalence of MDR tuberculosis, one component of the directly observed therapy-short course (DOTS) strategy, is proving to be an effective approach in controlling the emergence of MDR tuberculosis elsewhere in the world. 16 Supervised drug taking for all sputum smear positive cases in London may result in a decreased incidence of tuberculosis and MDR disease. The use of rapid molecular methods for identification of mycobacterial species and determination of rifampicin resistance could also support case management in London. 17 Determination of rifampicin resistance in smear positive sputum samples has been shown to be cost effective in areas of high prevalence. 18 19 Demographic data derived from Mycobnet must be interpreted with caution as completion rates of some variables are low-for example, the ethnic group of 45% of patients is unknown and place of birth is unknown in 57% of patients. Nonetheless, these data suggest a higher proportion of drug resistance among foreign born patients and those of black African, Oriental, and Indian subcontinent ethnic origin. Levels of drug resistance in these groups of people could therefore reflect either the prevalence in the country of origin 20 or resistance within specific communities in the UK. 21 22 A higher prevalence of HIV infection among some groups of foreign born patients may also have contributed to increased resistance. Matching against clinical tuberculosis enhanced surveillance data (using the national surveillance system developed recently that collects more detailed information on individual cases) 23 will improve the quality of this information in future.
The level of drug resistance in people with a previous history of tuberculosis is almost three times higher than in those known to have no previous history. The management of these patients may be more difficult and should concentrate on the use of rapid diagnostic tests for identification of Mycobacterium spp and rifampicin resistance, the administration of adequate and strictly supervised treatment, and the completion of treatment. Potential side effects of second and third line drugs and social, cultural, and psychological effects of prolonged isolation for a small number of cases may present considerable problems for the individual concerned.
The higher levels of resistance to isoniazid (both monoresistance and any resistance) in ethnic minority groups suggest that the recommendation by the British Thoracic Society 24 that ethambutol be included as a fourth drug in the initial phase of treatment for all non-white patients is sensible. However, the fact that 4% of even previously untreated white patients may be resistant to isoniazid suggests that consideration should be given to the inclusion of the fourth drug in the management of all patients with tuberculosis.
Patients with HIV infection are at increased risk of drug resistant tuberculosis. 25 This is probably not due to any increased susceptibility to MDR strains compared with fully sensitive strains of M tuberculosis but may reflect an increased spread of infection within institutional settings such as hospitals 12 13 26-28 accompanied by the rapid progression to active disease and longer duration of illness on average in those with drug resistant disease. Levels of drug resistance are similar in those reported not to have previously had tuberculosis and those whose previous history was unknown. Most of those in the second category are therefore unlikely to have been treated previously. Similarly, among those whose HIV status was unknown, levels of drug resistance were similar to those known to be HIV seronegative. Reports of isolates from patients with unknown HIV status and HIV seronegative cases have been grouped together, but may include a small number of HIV seropositive cases which were not ascertained.
As almost nine out of 10 isolates resistant to rifampicin were MDR, the use of rapid molecular techniques to identify rifampicin resistance in cases with risk factors for MDR is likely to prove highly effective in facilitating early detection of MDR cases. 18 The analysis of resistance to tuberculosis drugs in laboratory isolates using Mycobnet assesses the magnitude of the problem in the UK and indicates potential demographic risk factors. However, Mycobnet has limitations characteristic of any routine surveillance system such as incompleteness of information and reporting bias. Its information is useful for descriptive purposes, generating hypotheses and suggesting areas for further research, and ongoing monitoring of drug resistance. Regular matching of Mycobnet data in the future with data from the PHLS Enhanced Surveillance of Tuberculosis will make it possible to link clinical, demographic and microbiological information on all cases and, subsequently, to relate these further to treatment outcome. 28 Drug resistant M tuberculosis is difficult to treat, creates a financial burden to health services, 18 19 and poses a potential threat to the national tuberculosis control programme. Action for improving its control and prevention should be directed towards those who are at higher risk such as younger male patients, people who are resident in London, those who are foreign born, patients with a previous history of tuberculosis, and those infected with HIV. Molecular DNA/RNA amplification assays and molecular rifampicin resistance detection should be arranged for these patients to assure rapid diagnosis and prompt adequate treatment. 17 In addition, direct observation of treatment should be arranged for all sputum smear positive patients in high risk groups.
Supervised treatment can be provided in a variety of settings and is most likely to succeed if tailored to the individual patient's needs.
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